| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $451K | — | +41.5% |
| SG&A Expense | $447K | — | +32.3% |
| Operating Income | -$1.4M | — | +44.6% |
| Net Income | -$1.4M | — | +44.6% |
| EPS (Basic) | -$0.05 | — | +44.4% |
| EPS (Diluted) | -$0.05 | — | +44.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.1M | -8.6% | -31.2% |
| Current Assets | $8.5M | -8.7% | -29.1% |
| Total Assets | $12.8M | -5.6% | -13.7% |
| Current Liabilities | $2.2M | +18.3% | +36.4% |
| Total Liabilities | $2.2M | +15.9% | +38.8% |
| Stockholders' Equity | $10.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$979K | — | +48.1% |
| Capital Expenditures | $870K | — | +0.0% |
| Investing Cash Flow | -$126K | — | +14.6% |
| Financing Cash Flow | $350K | — | -96.2% |
| Free Cash Flow | -$1.8M | — | +32.9% |
| -23.7% |